[New perspectives for the treatment of age-related macular degeneration].
Currently, age-related macular degeneration (AMD) is untreatable, except for its neovascular complications. We review the primary pathogenesis of AMD and the pipeline of experimental interventions currently under way in clinical trials. They focus on four mechanisms: suppression of inflammation, visual cycle modification, prevention of oxidative damage and neuroprotection. Regulatory approval is years away, but the development may be accelerated by re-purposing of medications designed for systemic diseases.